R 722.15+ 1
〔摘 要〕 目的：研究依达拉奉联合丁苯酚治疗急性缺血性脑卒中的疗效及安全性。 方法：选择平顶山市第一人民医院 2020 年 1 月至 2022 月 1 月诊治的 92 例急性缺血性脑卒中患者，采用随机数字表法分为观察组和对照组，各 46 例。观察组 患者采用依达拉奉联合丁苯酚治疗，对照组患者选用丁苯酚治疗，比较两组患者疗效、并发症、美国国立卫生研究院脑卒 中量表（NIHSS）、改良巴氏指数（MBI）、Fugl–Meyer 运动功能评定量表（FMA）评分、S100 钙结合蛋白 B（S100B）、 髓鞘碱性蛋白（MBP）及 Tau 蛋白水平。 结果：观察组患者治疗总有效率高于对照组，差异具有统计学意义（P ＜ 0.05）； 观察组患者治疗后 NIHSS 评分低于对照组，MBI、FMA 评分高于对照组，差异具有统计学意义（P ＜ 0.05）；观察组患者 治疗后 S100B、MBP 水平低于对照组，Tau 蛋白水平高于对照组，差异具有统计学意义（P ＜ 0.05）；两组患者肝肾功能损伤、 消化道反应、皮疹、神经精神症状、血细胞异常发生率比较，差异无统计学意义（P ＞ 0.05）。 结论：依达拉奉联合丁苯 酚可改善急性缺血性脑卒中患者神经功能及颅脑损伤标志物水平，其疗效及安全性高于依达拉奉。
〔Abstract〕 Objective To study the curative effect and safety of edaravone combined with butylphenol in the treatment of acute ischemic stroke. Methods A total of 92 patients with acute ischemic stroke diagnosed and treated in the Pingdingshan First People's Hospital from January 2020 to January 2022 were selected and divided into an observation group and a control group by random number table method, with 46 cases in each group. The observation group was treated with edaravone combined with butylphenol, and the control group was treated with butylphenol. Efficacy, complications, National Institutes of Health stroke scale (NIHSS), modified barthel index (MBI), Fugl-Meyer assessment scale (FMA) score, S100 calcium binding protein B (S100B), myelin basic protein (MBP) and Tau protein levels were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P < 0.05). After treatment, the NIHSS score of the observation group was lower than that of the control group, and the MBI and FMA scores were higher than those of the control group, with statistical significance (P < 0.05). After treatment, the levels of S100B and MBP in the observation group were lower than those in the control group, and the levels of Tau protein were higher than that in the control group, with statistical significance (P < 0.05). There was no significant difference in the incidence of liver and kidney function injury, digestive tract reaction, rash, neuropsychiatric symptoms and abnormal blood cells between the two groups (P > 0.05). Conclusion Edaravone combined with butylphenol can improve the neurological function and the level of brain injury markers in patients with acute ischemic stroke, and its efficacy and safety are higher than edaravone.